Online citations, reference lists, and bibliographies.
← Back to Search

Solid Lipid Nanoparticles Modified With Amphipathic Chitosan Derivatives For Improved Stability In The Gastrointestinal Tract

Suping Qiu, D. Liang, F. Guo, Tiantian Deng, Tao-Xing Peng, Yuan Gao, X. Zhang, Haijun Zhong
Published 2018 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract In order to reduce enzymatic degradation and thereby improve the stability of solid lipid nanoparticles (SLNs) in the gastrointestinal tract (GIT), two comb-shaped amphiphilic macromolecular materials of N-stearyl-N-trimethyl chitosan (STMC) and N-linoleoyl-N-trimethyl chitosan (LTMC) were fabricated as emulsifier to modify SLNs. Some influence factors of lipolysis medium were investigated to establish in vitro lipolysis model for SLNs. The results showed that the lipolysis curves were fluctuant and variable when the amounts of SLNs were low. The lipolysis of SLNs increased with pancreatic enzyme activity ascending from 150 to 450 USPU/mL and achieved a threshold between 450 and 600 USPU/mL. The lipolysis of STMC-SLNs increased with the initial calcium concentration rising from 0 to 1.4 mM, but had no obvious change from 1.4 to 5 and 10 mM. Besides, SLNs lipolysis increased with bile acid salt and phospholipid concentration increasing. Finally, SLNs stability in GIT was tested with the optimized in vitro lipolysis model. The results revealed that as compared to P188-SLNs and Tween-SLNs, STMC-SLNs lipolysis decreased by 27.33% and 48.55%, and LTMC-SLNs decreased by 22.64% and 43.86%, respectively. Besides, the drug precipitations for STMC-SLNs and LTMC-SLNs were significantly decreased. These results demonstrated that both STMC-SLNs and LTMC-SLNs had excellent gastrointestinal stability.
This paper references
10.1016/j.cis.2008.08.012
Thin liquid films from aqueous solutions of non-ionic polymeric surfactants.
D. Exerowa (2009)
10.1016/S0169-409X(96)00489-9
Influence of lipolysis on drug absorption from the gastro-intestinal tract
Karen J. MacGregor (1997)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1016/j.ijpharm.2010.05.001
Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug.
Meirong Huo (2010)
10.1021/mp300331z
Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
H. Williams (2012)
10.1016/j.ejpb.2017.04.013
Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake
J. Baek (2017)
Simulating the digestion of lipid-based drug delivery systems (LBDDS): overview of in vitro lipolysis models.
K. Bolko (2014)
10.1016/j.jconrel.2014.07.037
'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
O. Feeney (2014)
10.3109/03639045.2014.972412
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract
V. Jannin (2015)
10.3109/10717544.2015.1048489
Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation
F. Guo (2016)
10.1007/s11095-014-1337-z
Solid Lipid Particles for Oral Delivery of Peptide and Protein Drugs II – The Digestion of Trilaurin Protects Desmopressin from Proteolytic Degradation
P. C. Christophersen (2014)
10.1016/j.ijpharm.2011.03.002
In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems.
A. T. Larsen (2011)
10.1016/J.ADDR.2007.04.007
Solid lipid nanoparticles as a drug delivery system for peptides and proteins.
A. Almeida (2007)
10.1002/jps.23205
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.
H. Williams (2012)
10.1016/j.ijbiomac.2016.02.004
Chitin and chitosan based polyurethanes: A review of recent advances and prospective biomedical applications.
A. Usman (2016)
10.1208/s12248-014-9672-x
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 6: Effects of Varying Pancreatin and Calcium Levels
P. Sassene (2014)
10.1016/j.colsurfb.2009.06.021
Surface active properties of chitosan and its derivatives.
M. Elsabee (2009)
10.4103/2230-973X.133047
Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery
J. Madan (2014)
10.1016/J.JCONREL.2004.08.010
Recent advances on chitosan-based micro- and nanoparticles in drug delivery.
S. Agnihotri (2004)
10.1016/j.ejpb.2013.08.013
Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art.
S. Weber (2014)
10.1080/03639045.2016.1220571
Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel
L. Shi (2017)
10.1016/j.cis.2008.10.005
Polymeric surfactants in disperse systems.
T. Tadros (2009)
10.1016/j.ijpharm.2012.11.024
In vitro digestion testing of lipid-based delivery systems: calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products.
R. Devraj (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar